Patents by Inventor Kozo YONEDA

Kozo YONEDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD147 ANTIBODY
    Publication number: 20230340118
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • Anti-CD147 antibody
    Patent number: 11661451
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: May 30, 2023
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke Fukuchi, Kayoko Nanai, Masato Amano, Kozo Yoneda, Yusuke Totoki, Shoji Yamamoto
  • Anti-CD147 antibody
    Patent number: 11459387
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: October 4, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke Fukuchi, Kayoko Nanai, Masato Amano, Kozo Yoneda, Yusuke Totoki, Shoji Yamamoto
  • ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
    Publication number: 20220177601
    Abstract: A novel anti-HER2 antibody-pyrrolobenzodiazepine (PBD) derivative conjugate, a medicine having therapeutic effect against tumor with the antibody-drug conjugate, and a method for treating a tumor by using the antibody-drug conjugate or medicine.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Naoya HARADA, Kozo YONEDA, Ichiro HAYAKAWA
  • ANTI-CD147 ANTIBODY
    Publication number: 20220106393
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 7, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
    Publication number: 20220016257
    Abstract: An object of the present invention is to provide an antibody specifically binding to CDH6 and having a high internalization activity, an antibody-drug conjugate comprising the antibody and a high antitumor activity, a pharmaceutical product having the antibody-drug conjugate and having a therapeutic effect on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. According to the present invention, it is possible to provide an anti-CDH6 antibody prepared having internalization activity, an anti-CDH6 antibody-drug conjugate prepared by connecting the anti-CDH6 antibody and a novel PBD derivative and exhibiting high anti-tumor activity, a pharmaceutical product and a therapeutic method for treating tumors using these.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 20, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Atsuko SAITO, Naoya HARADA, Kozo YONEDA, Ichiro HAYAKAWA, Masaki MEGURO, Fuminao DOI
  • ANTI-CD147 ANTIBODY
    Publication number: 20200362033
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: July 26, 2018
    Publication date: November 19, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO